Archive · 20 Jun 2025
New Breast Cancer Vaccine Shows Promising Early Results
Scientists are working on a new vaccine that could stop breast cancer.
This vaccine helps the body's defenses find and destroy cancer cells before they grow into tumors.
It works by targeting a milk protein called alpha-lactalbumin, which is found in some aggressive breast cancers.
Early tests show promise, but more testing is needed to make sure it's safe and works well for everyone.
If it works, it could help prevent certain types of breast cancer.
A breast cancer vaccine, developed with the Cleveland Clinic, has completed Phase 1 trials.
The vaccine aims to prevent cancerous tumors by training the immune system to destroy cancer cells.
Administered in three shots, it targets alpha-lactalbumin, a milk protein found in some breast cancers.
The vaccine targets alpha-lactalbumin, which is found in roughly 70% of triple-negative breast cancer cases.
Further trials are needed to confirm safety and effectiveness before broader use.
- Who
- Developed by Anixa Biosciences, Inc.
- What
- A breast cancer vaccine that aims to prevent tumor growth.
- When
- Phase 1 trials have been completed; further trials are planned.
- Where
- Developed in collaboration with the Cleveland Clinic.
- Why
- To prevent certain types of aggressive breast cancer.
Potential Benefits
Potential Challenges
Effectiveness vs. Safety
Potential Benefits
The vaccine could proactively prevent aggressive breast cancers.
Potential Challenges
Concerns about long-term safety and effectiveness in larger populations.
- Company
- Anixa Biosciences, Inc.
- Target
- Alpha-lactalbumin (milk protein)
- Type of Cancer
- Triple-negative breast cancer (TNBC)
- Administration
- Three shots
- Phase
- Phase 1 complete